abstract |
The present invention relates to ligation agents to VEGF, ligation agents to DLL4, bispecific ligation agents to VEGF / DLL4, and methods for using agents to treat diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and / or human DLL4. The present invention further provides methods for using agents to inhibit tumor growth. Methods for treating cancer are also described which comprise administering a therapeutically effective amount of an agent or antibody of the present invention to a patient having a tumor or cancer. |